News

Pfizer’s reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics (GBT) has been confirmed, with the

Pfizer vaults into sickle cell market as GBT deal confirmed

https://pharmaphorum.com/news/pfizer-vaults-into-sickle-cell-market-as-gbt-deal-confirmed/

News/ News/ News/ Oncology/ Sales and Marketing

Bayer bags swift OK for Nubeqa in metastatic prostate cancer

Phil Taylor Bayer, Erleada, Nubeqa, Oncology, Orion, Prostate cancer, regulatory approval, Xtandi 0 Comment

Bayer has won a key FDA approval to extend the use of its prostate cancer therapy Nubeqa, as

Bayer bags swift OK for Nubeqa in metastatic prostate cancer

https://pharmaphorum.com/news/bayer-bags-swift-ok-for-nubeqa-in-metastatic-prostate-cancer/

News/ News/ Sales and Marketing

Pfizer bid for sickle cell drug developer GBT said to be imminent

Phil Taylor Global Blood Therapeutics, M&A, Oxbryta, Pfizer, sickle cell disease 0 Comment

Pfizer is on the brink of announcing a deal to buy Global Blood Therapeutics (GBT) and its oral

Pfizer bid for sickle cell drug developer GBT said to be imminent

https://pharmaphorum.com/news/pfizer-bid-for-sickle-cell-drug-developer-gbt-said-to-be-imminent/

News/ News/ News/ Patients/ Sales and Marketing

Bayer tops pharma rankings for diversity, inclusivity

Phil Taylor alva, Astellas, Bayer, diversity and inclusion, Eli Lilly, Gilead Sciences, pharma reputation, Sanofi, Teva 0 Comment

The largest pharma companies have all set themselves ambitious targets in recent years to improve representation for women

Bayer tops pharma rankings for diversity, inclusivity

https://pharmaphorum.com/news/bayer-tops-pharma-rankings-for-diversity-inclusivity/

Radiology technician examens mammography test

News/ News/ News/ Oncology/ Sales and Marketing

AZ, Merck get EU nod for Lynparza as adjuvant breast cancer therapy

Phil Taylor adjuvant, AstraZeneca, breast cancer, EU, Lynparza, Merck & Co, Oncology, targeted oncology 0 Comment

The European Commission has cleared AstraZeneca and Merck & Co’s Lynparza as an adjuvant treatment for breast cancer,

AZ, Merck get EU nod for Lynparza as adjuvant breast cancer therapy

https://pharmaphorum.com/news/az-merck-get-eu-nod-for-lynparza-as-adjuvant-breast-cancer-therapy/

Market Access/ News/ News/ News/ Sales and Marketing

Pressure rises on Lucentis, as Coherus biosimilar gets FDA nod

Phil Taylor biosimilar, Byooviz, Cimerli, Coherus, Lucentis, Novartis, Roche, Samsung Bioepis 0 Comment

The US FDA has approved a new biosimilar of Roche and Novartis’ blockbuster ophthalmology therapy Lucentis – Coherus

Pressure rises on Lucentis, as Coherus biosimilar gets FDA nod

https://pharmaphorum.com/news/pressure-rises-on-lucentis-as-coherus-biosimilar-gets-fda-nod/

News/ News/ News/ Oncology/ Sales and Marketing

Gilead Sciences’ push into oncology is paying off, as Veklury falters

Phil Taylor Gilead Sciences, Sales and Marketing, Tecartus, Trodelvy, Veklury, Yescarta 0 Comment

Gilead Sciences’ investment in oncology has started to provide a solid return, with sales of cancer therapies breaching

Gilead Sciences’ push into oncology is paying off, as Veklury falters

https://pharmaphorum.com/news/gilead-sciences-push-into-oncology-is-paying-off-as-veklury-falters/

News/ News/ News/ Patients/ Sales and Marketing

US government buys 66m doses of Moderna’s Omicron booster

Phil Taylor BioNTech, coronavirus, COVID-19, COVID-19 vaccine, Moderna, Omicron, Pfizer, US 0 Comment

The Biden administration has confirmed its plans to start a booster vaccination campaign in the autumn, and placed

US government buys 66m doses of Moderna’s Omicron booster

https://pharmaphorum.com/news/us-government-buys-66m-doses-of-modernas-omicron-booster/

News/ News/ Sales and Marketing

AstraZeneca raises 2022 guidance, names Demaré as non-exec chair

Phil Taylor AstraZeneca, Enhertu, Evusheld, Farxiga, Financial, Oncology, Rare diseases 0 Comment

AstraZeneca chief executive Pascal Soriot said this morning that strong revenue increases in 2022 – fuelled by its

AstraZeneca raises 2022 guidance, names Demaré as non-exec chair

https://pharmaphorum.com/news/astrazeneca-raises-2022-guidance-names-demare-as-non-exec-chair/

1 2 3 4 ›»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

News

Login